New treatments to heal bone damage from cancer radiation therapy
Novel therapeutic approaches to remediate radiotherapy-induced bone necrosis
This study is looking at new treatments to help heal bone damage in African-American patients with oropharyngeal cancer who have had radiation therapy, aiming to improve their recovery and overall health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10912194 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies to address osteoradionecrosis (ORN), a severe complication that affects patients with oropharyngeal cancer (OPC) after receiving radiotherapy. The study aims to evaluate the effectiveness of injectable osteoanabolic drugs in promoting bone healing specifically in African-American patients, who are at a higher risk for ORN due to lower levels of circulating progenitor cells. By understanding how these therapies can improve bone healing, the research seeks to enhance overall survival outcomes for patients suffering from OPC. The approach includes assessing the efficacy of these new treatments in a controlled setting to determine their potential benefits.
Who could benefit from this research
Good fit: Ideal candidates for this research are African-American patients diagnosed with oropharyngeal cancer who are undergoing or have undergone radiotherapy.
Not a fit: Patients who do not have oropharyngeal cancer or those who have not received radiotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve bone healing and survival rates for patients with oropharyngeal cancer who experience complications from radiation therapy.
How similar studies have performed: Previous research has shown promise in using injectable therapies for bone healing, but this specific approach targeting ORN in African-American patients is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Akintoye, Sunday O — University of Pennsylvania
- Study coordinator: Akintoye, Sunday O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.